chr2:211430972:> Detail (hg38) (ERBB4)

Information

Genome

Assembly Position
hg19 chr2:212,295,697-212,578,308 
hg38 chr2:211,430,972-211,713,583

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
melanoma Lapatinib D Predictive Supports Sensitivity/Response Somatic 4 19718025 Detail
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 pat... CIViC Evidence Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
Genome
hg38
Position
chr2:211,430,972-211,713,583
Variant Type
snv
Variant (CIViC) (CIViC Variant)
MUTATION
Transcript 1 (CIViC Variant)
ENST00000342788.4
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/310
Summary (CIViC Variant)
ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.
Genome browser